JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Innoviva Inc

Geschlossen

BrancheGesundheitswesen

17.55 -1.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

17.38

Max

17.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

110M

64M

Verkäufe

12M

100M

KGV

Branchendurchschnitt

31.088

37.003

Gewinnspanne

63.508

Angestellte

127

EBITDA

111M

84M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+114.81% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-50M

1.1B

Vorheriger Eröffnungskurs

18.68

Vorheriger Schlusskurs

17.55

Nachrichtenstimmung

By Acuity

42%

58%

157 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Innoviva Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Okt. 2025, 23:28 UTC

Heiße Aktien

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. Okt. 2025, 23:07 UTC

Ergebnisse

Prudential PLC 3Q New Business Profit Up 13%

30. Okt. 2025, 00:00 UTC

Ergebnisse

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. Okt. 2025, 00:00 UTC

Ergebnisse

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. Okt. 2025, 00:00 UTC

Ergebnisse

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. Okt. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. Okt. 2025, 23:40 UTC

Ergebnisse

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. Okt. 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. Okt. 2025, 23:25 UTC

Ergebnisse

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. Okt. 2025, 22:51 UTC

Ergebnisse

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. Okt. 2025, 22:45 UTC

Ergebnisse

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. Okt. 2025, 22:41 UTC

Ergebnisse

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. Okt. 2025, 22:41 UTC

Ergebnisse

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. Okt. 2025, 22:09 UTC

Ergebnisse

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. Okt. 2025, 22:08 UTC

Market Talk
Ergebnisse

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. Okt. 2025, 21:58 UTC

Ergebnisse

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. Okt. 2025, 21:58 UTC

Ergebnisse

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. Okt. 2025, 21:57 UTC

Ergebnisse

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. Okt. 2025, 21:54 UTC

Ergebnisse

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. Okt. 2025, 21:46 UTC

Ergebnisse

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. Okt. 2025, 21:43 UTC

Ergebnisse

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. Okt. 2025, 21:43 UTC

Ergebnisse

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. Okt. 2025, 21:42 UTC

Ergebnisse

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. Okt. 2025, 21:42 UTC

Ergebnisse

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. Okt. 2025, 21:41 UTC

Ergebnisse

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. Okt. 2025, 21:41 UTC

Ergebnisse

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. Okt. 2025, 21:41 UTC

Ergebnisse

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. Okt. 2025, 21:41 UTC

Ergebnisse

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. Okt. 2025, 21:40 UTC

Ergebnisse

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. Okt. 2025, 21:39 UTC

Ergebnisse

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Peer-Vergleich

Kursveränderung

Innoviva Inc Prognose

Kursziel

By TipRanks

114.81% Vorteil

12-Monats-Prognose

Durchschnitt 38 USD  114.81%

Hoch 55 USD

Tief 17 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Innoviva Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

3

Buy

0

Halten

1

Sell

Technischer Score

By Trading Central

18.57 / 18.75Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

157 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat